A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients

International Journal of Cancer

Volumn 130, Issue 8, 2012, Pages 1861-1869

  Eijsink, J J H ^a   Lendvai, Á ^a   Deregowski, V ^b   Klip, H G ^a   Verpooten, G ^b   Dehaspe, L ^b   De Bock, G H ^a   Hollema, H ^a   Van Criekinge, W ^b   Schuuring, E ^a   Van Der Zee, A G J ^a   Wisman, G B A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b OncoMethylome Sciences SA   (Belgium)

Author keywords

cervical cancer; CIN; HPV; marker; methylation; openarray

Indexed keywords

BIOLOGICAL MARKER; DNA; PROTEIN EPB41L3; PROTEIN JAM3; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SCREENING; CANCER TISSUE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA METHYLATION; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TUMOR GENE; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; ALPHAPAPILLOMAVIRUS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; CYTODIAGNOSIS; DNA METHYLATION; FEMALE; GENOTYPE; HELA CELLS; HUMANS; MICROFILAMENT PROTEINS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84857500119     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26326     Document Type: Article

References (27)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV,. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65.
2. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J,. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008; 111: 167-77.
3. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL,. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-88.
4. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van GK, Boon ME, Ruitinga W, van BM, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-72.
5. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA,. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002; 288: 1749-57.
6. Baylin SB, Ohm JE,. Epigenetic gene silencing in cancer†"a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-16.
7. Reesink-Peters N, Wisman GB, Jeronimo C, Tokumaru CY, Cohen Y, Dong SM, Klip HG, Buikema HJ, Suurmeijer AJ, Hollema H, Boezen HM, Sidransky D, et al. Detecting cervical cancer by quantitative promoter hypermethylation assay on cervical scrapings: a feasibility study. Mol Cancer Res 2004; 2: 289-95.
8. Wisman GB, Nijhuis ER, Hoque MO, Reesink-Peters N, Koning AJ, Volders HH, Buikema HJ, Boezen HM, Hollema H, Schuuring E, Sidransky D, Van der Zee AG,. Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer 2006; 119: 1908-14.
9. Wentzensen N, Sherman ME, Schiffman M, Wang SS,. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2008; 112: 293-9.
10. Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, Liu J, Chan MW, Chu TY, Sun CA, Chang CC, Yu MH,. Identification of novel DNA methylation markers in cervical cancer. Int J Cancer 2008; 123: 161-7.
11. Wang SS, Smiraglia DJ, Wu YZ, Ghosh S, Rader JS, Cho KR, Bonfiglio TA, Nayar R, Plass C, Sherman ME,. Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning. Cancer Res 2008; 68: 2489-97.
12. Hoque MO, Kim MS, Ostrow KL, Liu J, Wisman GB, Park HL, Poeta ML, Jeronimo C, Henrique R, Lendvai A, Schuuring E, Begum S, et al. Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res 2008; 68: 2661-70.
13. Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, Lieber A, Kiviat N,. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 114-23.
14. Ongenaert M, Wisman GB, Volders HH, Koning AJ, Zee AG, van Criekinge W, Schuuring E,. Discovery of DNA methylation markers in cervical cancer using relaxation ranking. BMC Med Genom 2008; 1: 57.
15. Yang N, Eijsink JJ, Lendvai A, Volders HH, Klip H, Buikema HJ, van Hemel BM, Schuuring E, Van der Zee AG, Wisman GB,. Methylation markers for CCNA1 and C13ORF18 are strongly associated with high-grade cervical intraepithelial neoplasia and cervical cancer in cervical scrapings. Cancer Epidemiol Biomarkers Prev 2009; 18: 3000-7.
16. Morrison T, Hurley J, Garcia J, Yoder K, Katz A, Roberts D, Cho J, Kanigan T, Ilyin SE, Horowitz D, Dixon JM, Brenan CJ,. Nanoliter high throughput quantitative PCR. Nucleic Acids Res 2006; 34: e123.
17. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, Garcia-Sanz R, van Krieken JH, Droese J, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-317.
18. Woodman CB, Collins SI, Young LS,. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007; 7: 11-22.
19. Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlee F,. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res 2009; 40: 478-85.
20. Hesselink AT, Heideman DA, Steenbergen RD, Coupe VM, Overmeer RM, Rijkaart D, Berkhof J, Meijer CJ, Snijders PJ,. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res 2011; 17: 2459-65.
21. Brink AA, Meijer CJ, Wiegerinck MA, Nieboer TE, Kruitwagen RF, van KF, Fransen DN, Hesselink AT, Berkhof J, Snijders PJ,. High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J Clin Microbiol 2006; 44: 2518-23.
22. Eijsink JJ, Yang N, Lendvai A, Klip HG, Volders HH, Buikema HJ, van Hemel BM, Voll M, Bennink HJ, Schuuring E, Wisman GB, Van der Zee AG,. Detection of cervical neoplasia by DNA methylation analysis in cervico-vaginal lavages, a feasibility study. Gynecol Oncol 2011; 120: 280-3.
23. Bazzoni G,. The JAM family of junctional adhesion molecules. Curr Opin Cell Biol 2003; 15: 525-30.
24. Wisman GB, Knol AJ, Helder MN, Krans M, de Vries EG, Hollema H, de Jong S, Van der Zee AG,. Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer. Int J Cancer 2001; 91: 658-64.
25. Renaud S, Loukinov D, Abdullaev Z, Guilleret I, Bosman FT, Lobanenkov V, Benhattar J,. Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res 2007; 35: 1245-56.
26. Heller G, Geradts J, Ziegler B, Newsham I, Filipits M, Markis-Ritzinger EM, Kandioler D, Berger W, Stiglbauer W, Depisch D, Pirker R, Zielinski CC, et al. Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat 2007; 103: 283-91.
27. Bernkopf DB, Williams ED,. Potential role of EPB41L3 (protein 4.1B/Dal-1) as a target for treatment of advanced prostate cancer. Expert Opin Ther Targets 2008; 12: 845-53.